124 related articles for article (PubMed ID: 8103784)
21. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
22. Endometrial carcinoma associated with hyperplasia--immunohistochemical study of angiogenesis and p53 expression.
Kaku T; Kamura T; Hirakawa T; Sakai K; Amada S; Kobayashi H; Nakano H
Gynecol Oncol; 1999 Jan; 72(1):51-5. PubMed ID: 9889029
[TBL] [Abstract][Full Text] [Related]
23. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma.
Chan WK; Mole MM; Levison DA; Ball RY; Lu QL; Patel K; Hanby AM
J Pathol; 1995 Nov; 177(3):241-6. PubMed ID: 8551385
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
25. Atypical endometrial hyperplasia shares genomic abnormalities with endometrioid carcinoma by comparative genomic hybridization.
Baloglu H; Cannizzaro LA; Jones J; Koss LG
Hum Pathol; 2001 Jun; 32(6):615-22. PubMed ID: 11431716
[TBL] [Abstract][Full Text] [Related]
26. [Immunohistochemical study of PCNA, p53 gene product and c-erbB-2 gene product in endometrial carcinoma].
Miyazaki M
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Apr; 48(4):269-76. PubMed ID: 8936111
[TBL] [Abstract][Full Text] [Related]
27. The value of curettage in diagnosis of endometrial hyperplasia.
Xie X; Lu WG; Ye DF; Chen HZ; Fu YF
Gynecol Oncol; 2002 Jan; 84(1):135-9. PubMed ID: 11748989
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women.
Konishi I; Koshiyama M; Mandai M; Kuroda H; Yamamoto S; Nanbu K; Komatsu T; Matsushita K; Rao CV; Mori T
Gynecol Oncol; 1997 May; 65(2):273-80. PubMed ID: 9159337
[TBL] [Abstract][Full Text] [Related]
29. beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.
Saegusa M; Hashimura M; Yoshida T; Okayasu I
Br J Cancer; 2001 Jan; 84(2):209-17. PubMed ID: 11161379
[TBL] [Abstract][Full Text] [Related]
30. [Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease].
Sasaki H
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Aug; 45(8):763-75. PubMed ID: 8371007
[TBL] [Abstract][Full Text] [Related]
31. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
32. [Characteristic of cystic glandular hyperplasia as a precursor of endometrial carcinoma].
Yokosuka K; Teshima H; Yamakawa Y; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Nov; 46(11):1241-6. PubMed ID: 7844442
[TBL] [Abstract][Full Text] [Related]
33. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
Ørbo A; Kaino T; Arnes M; Larsen K; Pettersen I; Moe B
Acta Obstet Gynecol Scand; 2009; 88(11):1234-42. PubMed ID: 19900140
[TBL] [Abstract][Full Text] [Related]
34. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
35. Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1.
Briese J; Schulte HM; Bamberger CM; Löning T; Bamberger AM
Int J Gynecol Pathol; 2006 Apr; 25(2):161-9. PubMed ID: 16633066
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma.
Isaka K; Nishi H; Nakai H; Nakada T; Feng Li Y; Ebihara Y; Takayama M
Cancer; 2003 Jan; 97(1):79-89. PubMed ID: 12491508
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression.
Mora LB; Diaz JI; Cantor AB; Nicosia SV
Ann Clin Lab Sci; 1999; 29(4):308-15. PubMed ID: 10528831
[TBL] [Abstract][Full Text] [Related]
38. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
39. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
[TBL] [Abstract][Full Text] [Related]
40. Silencing of Cathepsin B suppresses the proliferation and invasion of endometrial cancer.
Bao W; Fan Q; Luo X; Cheng WW; Wang YD; Li ZN; Chen XL; Wu D
Oncol Rep; 2013 Aug; 30(2):723-30. PubMed ID: 23708264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
